This study aimed to evaluate the risk of doxorubicin-induced cardiotoxicity in newly diagnosed breast cancer patients with type 2 diabetes receiving dapagl
8 January 2022 in Irish Journal of Medical Science (1971 -)
Insulin-like growth factor-1 (IGF-1) and growth hormone release is elevated in acromegaly, a chronic condition. Our objective was to study the correlation between carotid femoral pulse wave velocity (CF-PWV) and galectin-3 level in acromegaly patients. This protein is believed to alter in response to early inflammation and atherosclerosis. Our study was planned as a prospective, single-center cross-sectional study. Our study comprised 40 healthy controls and 40 newly diagnosed acromegaly patients ranging in age from 18 to 65 years old at Adana City Training and Research Hospital. The patients’ IGF-1, growth hormone, hemogram, and biochemistry values were assessed. Human galectin-3 kits and the Enzyme-Linked Immunosorbent Assay were used to measure the amount of galectin-3. Patients underwent CF-PWV assessments with the use of Doppler ultrasonography and concurrent electrocardiography. Our investigation indicated that acromegaly patients had greater levels of the fibrosis and inflammation indicator galectin-3 as well as the gold standard indication of arterial stiffness, CF-PWV. We observed a link between blood galectin-3 level and both IGF-1 level and CF-PWV measures in the correlation analysis. Galectin-3 has the potential to be a novel biomarker for the diagnosis and prognosis of cardiovascular disease in acromegaly patients, as well as a therapeutic target for the development of this disease.
Aim: Diabetes mellitus (DM) is associated with the development and progression of metabolic dysfunction-associated steatotic liver disease (MASLD). In our study, we aimed to evaluate the findings of MASLD and fibrosis according to liver ultrasound (USG) imaging, FIB-4 score and fibroscan findings in patients with type 2 DM followed in our internal medicine clinic. Methods: In our retrospective and cross-sectional study, 1282 patients diagnosed with type 2 DM whose anamnesis and previous examinations did not constitute an obstacle for inclusion in the study were included. The abdominal USG imaging of the patients were analysed from the system and the FIB-4 score was calculated. Liver stiffness (LS) measurements were performed with FibroScan® Mini 430 device (Echosens, France). Results: USG imaging was performed in 474 (36.9%) of 1282 patients and MASLD was diagnosed in 341 (71.9%) of these patients. FIB-4 score> was 1.3 in 45 of 341 patients diagnosed with MASLD. Fibroscan imaging was performed in 231 of 341 patients with MASLD. In 52 (22.5%) of 231 patients, LS measurements> were 8 kPa Conclusion: We recommend early screening of MASLD, which is associated with advanced fibrosis and increased cardiovascular mortality and morbidity in patients with DM, with liver USG, measurement of FIB-4 score and evaluation of LS with fibroscan in centres where possible.
23 March 2022 in Archives of Endocrinology and Metabolism
Objective: Graves’ ophthalmopathy (GO) is a vision-threatening finding observed in approximately half of Graves’ disease patients. The pathophysiology of GO is unclear, and one of the suspected factors is oxidative stress. In our study, we compared the relationship between proptosis and SH-SS in patients diagnosed with GO. Materials and methods: In this prospective study, 40 recently diagnosed Graves’ disease patients with proptosis, 40 recently diagnosed Graves’ disease patients without GO and 30 healthy individuals with similar demographic characteristics were [...] ABSTRACT Objective: Graves’ ophthalmopathy (GO) is a vision-threatening finding observed in approximately half of Graves’ disease patients. The pathophysiology of GO is unclear, and one of the suspected factors is oxidative stress. In our study, we compared the relationship between proptosis and SH-SS in patients diagnosed with GO. Materials and methods: In this prospective study, 40 recently diagnosed Graves’ disease patients with proptosis, 40 recently diagnosed Graves’ disease patients without GO and 30 healthy individuals with similar demographic characteristics were
30 June 2025 in Cukurova Anestezi ve Cerrahi Bilimler Dergisi
Aim: Contrast-induced acute kidney injury (CI-AKI) is associated with increased risk of morbidity and mortality and specific treatments are needed. In our study, we aimed to investigate the association of sodium-glucose cotransporter-2 inhibitors (SGLT2-I) use with the development of CI-AKI due to coronary angiography (CAG) in patients with DM. Methods: A total of 516 type 2 diabetes mellitus (DM) patients, including 250 SGLT2-I users and 266 non-SGLT2-I users, were included in our retrospective and cross-sectional study. Results: The study groups were divided into CI-AKI (+) and CI-AKI (-). SGLT2-I use was statistically significantly higher in the CI-AKI (-) group. Multivariate logistic regression analysis showed that SGLT2-I use reduced the probability of CI-AKI by 83.8%. Conclusion: Our findings suggest that SGLT2-Is may significantly reduce the risk of CI-AKI in diabetic patients undergoing CAG. In conclusion, the use of SGLT2-I may have a protective and preventive effect against the development of CI-AKI.